(Circulation. 2001;103:1198.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Common Genetic Variation in ABCA1 Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease
From the Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada (S.M.C., K.Y.Z., M.R.H.); the Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands (A.H.Z.); Montreal Genome Centre, McGill University Health Centre, Montreal, Canada (J.C.E., T.J.H.); the Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands (H.O.F.M., M.v.W., M.v.D., J.J.P.K.); Xenon Genetics, Inc, Vancouver, Canada (K.R., A.B.-W.); the Department of Cardiology, Leiden University Medical Center and Interuniversity Cardiology Institute, Leiden, the Netherlands (J.W.J.); and the Cardiovascular Genetics Laboratory, McGill University Health Centre, Montreal, Canada (J.G.).
Correspondence to Michael R. Hayden, Centre for Molecular Medicine and Therapeutics, 980 W. 28th Avenue, Vancouver, BC, Canada V5Z 4H4. E-mail mrh{at}cmmt.ubc.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Low plasma HDL cholesterol (HDL-C) is associated with an increased risk of coronary artery disease (CAD). We recently identified the ATP-binding cassette transporter 1 (ABCA1) as the major gene underlying the HDL deficiency associated with reduced cholesterol efflux. Mutations within the ABCA1 gene are associated with decreased HDL-C, increased triglycerides, and an increased risk of CAD. However, the extent to which common variation within this gene influences plasma lipid levels and CAD in the general population is unknown.
Methods and Results—We examined the phenotypic effects of single nucleotide polymorphisms in the coding region of ABCA1. The R219K variant has a carrier frequency of 46% in Europeans. Carriers have a reduced severity of CAD, decreased focal (minimum obstruction diameter 1.81±0.35 versus 1.73±0.35 mm in noncarriers, P=0.001) and diffuse atherosclerosis (mean segment diameter 2.77±0.37 versus 2.70±0.37 mm, P=0.005), and fewer coronary events (50% versus 59%, P=0.02). Atherosclerosis progresses more slowly in carriers of R219K than in noncarriers. Carriers have decreased triglyceride levels (1.42±0.49 versus 1.84±0.77 mmol/L, P=0.001) and a trend toward increased HDL-C (0.91±0.22 versus 0.88±0.20 mmol/L, P=0.12). Other single nucleotide polymorphisms in the coding region had milder effects on plasma lipids and atherosclerosis.
Conclusions—These data suggest that common variation in ABCA1 significantly influences plasma lipid levels and the severity of CAD.
Key Words: ABC transporters • coronary disease • lipids • genetics
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
HDL cholesterol (HDL-C) was first suggested to protect against the development of coronary artery disease (CAD) 25 years ago.1 Since then, a strong inverse relationship between plasma HDL-C levels and CAD has been confirmed in a large number of epidemiological studies.2 3 Low plasma HDL-C is now generally accepted as a strong and independent risk factor for the development of premature atherosclerosis.
A rare form of genetic HDL deficiency is Tangier
disease,4 which has been
diagnosed in 
60 patients worldwide and is associated with an almost
complete absence of HDL-C. We and others have recently identified
mutations in the ATP-binding cassette transporter 1 gene
(ABC1,
ABCA1) as the molecular defect
in Tangier
disease5 6 7
and familial HDL deficiency associated with reduced cholesterol efflux
(FHA).5 8
Individuals heterozygous for mutations in the ABCA1 gene have decreased HDL-C, increased triglycerides (TG), and an increased risk of CAD.9 Specific variants associated with complete or near-complete loss of ABCA1 function are not found at a high frequency in patients presenting with low HDL-C.9 However, the extent to which common variation in the ABCA1 gene influences these phenotypes in the general population is uncertain. Thus, we sought to address whether variants having milder effects on ABCA1 function influence plasma lipid levels and risk of CAD.
We identified numerous single-nucleotide polymorphisms throughout the coding region (cSNPs) of the ABCA1 gene and examined the phenotypic effects of 9 nonsynonymous (ie, those that change an amino acid) cSNPs in a large, ethnically uniform cohort. We report here that a common ABCA1 cSNP, R219K, is associated with decreased TG, increased HDL-C and, importantly, a decreased progression of atherosclerosis and a reduced risk of coronary events, suggesting that common genetic variants in ABCA1 may influence these clinical outcomes in the general population.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
During the course of sequencing 16 Tangier disease and FHA probands, we identified 16 cSNPs. Sequencing 16 individuals yields a 97% chance of identifying a variant present at a frequency
10%.10 Thus, it is likely
that all the common ABCA1 cSNPs
have been identified. We studied the effects of these cSNPs on the
baseline lipid parameters of the cohort of 804 Dutch men with proven
CAD who participated in the Regression Growth Evaluation Statin Study
(REGRESS); these subjects were described
previously.11 For replication studies with the R219K variant, we genotyped 3 smaller cohorts. Because reliable, standardized information on CAD was not available on all cohorts, we did not include CAD in the replication analysis. The cohorts comprised individuals of European descent with familial hypercholesterolemia seen at the lipid clinic in Vancouver, a group of French Canadians with CAD and low HDL-C (<0.86 mmol/L), and a random sample of French Canadians without clinical manifestations of CAD who were unselected for plasma lipid levels. All individuals known to be diabetic or have the apoE2 allele, a body mass index (BMI) >30 kg/m2, or TG>5 mmol/L were excluded. Comparisons were performed on a case-control basis to avoid stratification by ethnicity or other demographic factors. All individuals gave informed consent.
CAD Measurements
Computer-assisted quantitative coronary angiography
was performed as previously
described.11 The mean
segment diameter (MSD) measures the average luminal diameter along the
vessel and reflects diffuse atherosclerotic differences. The minimum
obstruction diameter (MOD) represents the smallest vessel diameter at
an obstructed site and assesses focal atherosclerotic changes. Larger
MSD and MOD measurements reflect less vessel occlusion. Events during
the study (death, myocardial infarction, unscheduled coronary
angioplasty or bypass surgery [PTCA, CABG], and stroke/transient
ischemic attack) were also examined.
cSNP Screening
We identified a restriction enzyme whose cleavage
pattern was altered by each variant or employed a mismatch technique
allowing restriction fragment length polymorphism analysis. The
conditions of all assays are described in
Table 1
.
|
To screen the V399A, V771M, T774P, I883M, and E1172D cSNPs, TaqMan-based assays12 were developed. Fluorogenic hybridization probes for each allele were labeled with different fluorescent reporter dyes (6-carboxy-fluorescein or 6-carboxy-4,7,2',7'-tetrochloro-fluorescein) at the 5' terminus and with a common quencher dye (6-carboxy-N,N,N',N',tetramethyl rhodamine) at the 3' terminus. The fluorescence from each reaction was normalized to the signal from the no-template controls.13 The difference in the measured fluorescence intensity between the 2 probes allows for accurate allele calling compared with genotype standards included on each plate.
Cellular Cholesterol Efflux
Cholesterol efflux was measured in a series of Dutch
individuals with HDL-C less than the fifth percentile, essentially as
described previously.8
Measurements are reported as the percentage efflux relative to the
average of 2 healthy controls included within the same experiment. All
individuals had an efflux in the normal range (>60% of controls).
None had mutations in ABCA1
associated with Tangier disease or FHA.
Statistics
The baseline characteristics of the patients with
each genotype for each cSNP were compared using 1-way ANOVA and the
2 test. Subsequent comparisons between
carriers and noncarriers were made using a
t test. Probability values
unadjusted for multiple comparisons are presented to allow readers to
reach their own conclusions regarding significance. The cumulative
event incidence was compared using the log-rank test. The relationships
between age and HDL-C or efflux were investigated using a linear
regression model, and the slopes of the regression lines were compared
using covariance analysis (interaction between age and genotype).
Randomization to placebo and pravastatin in the REGRESS cohort was
assessed by 2 analysis and was equivalent
for all genotypes except R1587K, in which a lower proportion of
carriers was randomized to pravastatin. Events during the trial were
also analyzed for the placebo and pravastatin subgroups separately,
with similar effects in each subgroup. Thus, the combined results are
presented. All lipid levels are expressed in mmol/L, and all values are
reported as the mean±SD. The population-attributable risk for R219K is
calculated from the sum of each genotype frequency multiplied by its
risk (relative to KK). The population-attributable risk is calculated
as [sum-1]/sum.
For replication studies, KK and RR genotypes were compared by 1-tailed t test to test for the specific differences seen in the REGRESS cohort. Although each cohort was small, statistical power was increased by combining the results in a meta-analysis (Meta 5.3).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Identification and Distribution of ABCA1 cSNPs
A total of 16 cSNPs were identified in the 6.8-kb coding region (
1 cSNP every 425 bp). Because nonsynonymous cSNPs are
most likely to be associated with functional effects, we focused on
those 10
(Table 2). The nonsynonymous cSNPs are nonrandomly
distributed throughout the protein
(Figure 1).
|
|
The R219K Polymorphism Is Associated With a
Decreased Severity of CAD
The G1051A polymorphism results in the substitution of
a lysine for arginine at amino acid 219 of the ABCA1 protein (R219K;
Table 2
). There were no significant differences in blood
pressure (systolic and diastolic), plasma glucose levels, or smoking
behavior between the genotypes. BMI was slightly higher in
heterozygotes compared with either homozygous genotype.
The K allele of the R219K polymorphism was associated
with a decreased severity of CAD
(Table 3), as indicated by an increased MSD and MOD. The
angiographic data were paralleled by differences in clinical events. A
smaller percentage of individuals homozygous for the K allele had a
myocardial infarction before the trial, although this did not reach
significance
(Table 3). Carriers had 29% fewer events (death, myocardial
infarction, unscheduled PTCA or CABG, stroke, or transient ischemic
attack) during the study compared with noncarriers
(Figure 2, P=0.07).
Furthermore, total events (prior myocardial infarction or event during
the trial) were significantly reduced in KK compared with RR
individuals (odds ratio for KK, 0.45; 95% CI, 0.22 to 0.91).
Conversely, this translates to a 2-fold increased risk (odds ratio,
2.2; 95% CI, 1.1 to 4.4) for RR individuals relative to
KK.
|
|
From the increased relative risk associated with the RK and RR genotypes compared with the KK genotype, the population-attributable risk was calculated. For the R219K variant, the population-attributable risk is 5.3%, suggesting that the frequency of CAD events would be 5.3% lower if all individuals carried the KK genotype.
If the K allele of the R219K variant is protective against CAD, we might expect its frequency to be reduced in this cohort, which was selected for CAD. Indeed, the genotype frequencies observed for this variant are not consistent with Hardy-Weinberg equilibrium (P=0.004), with fewer KK individuals than would be expected (observed, 36; expected, 51, P=0.04).
Association of the R219K Polymorphism With
Plasma Lipid Levels
TG were significantly lower in the carriers of the K
allele
(Table 4). We previously showed that decreased ABCA1
function is associated with increased TG
levels.9 There were no
differences in mean HDL-C levels in the group as a whole
(Table 4).
|
The phenotype of individuals heterozygous for
ABCA1 mutations becomes more
pronounced in older
individuals.9 Therefore, we
further examined HDL-C levels in age-defined subgroups. In individuals
younger than the median age of the cohort (56.7 years), carriers
(RK+KK) had a trend toward increased HDL-C compared with noncarriers
(0.91±0.22 mmol/L in RK+KK versus 0.88±0.20 mmol/L in RR,
P=0.12) that was no longer
evident in those above the median age (0.94±0.23 mmol/L for RK+KK
versus 0.96±0.24 mmol/L in RR,
P=0.37). Linear regression
analysis of HDL-C and age showed that in RR individuals, HDL-C was
positively correlated with age. In contrast, this relationship was not
apparent in carriers
(Figure 3A), such that the HDL-C difference between the
genotypes was lost in the older individuals
(P comparing
slopes=0.04).
|
The changes in HDL-C with age are matched by trends in
cholesterol efflux with age
(Figure 3B). In RR individuals (n=16), cholesterol efflux
increased with age, whereas in RK+KK individuals (n=22), efflux
decreased with age (P comparing
slopes=0.07). In younger individuals, cholesterol efflux and HDL-C were
increased in KK compared with RR individuals, which suggests that the
R219K variant may be especially protective against premature
CAD.
Age Subgroup Analysis Indicates CAD Progresses
More Slowly in R219K Carriers
In the noncarriers, MOD and MSD decreased significantly
with age, reflecting increased atherosclerosis in the older individuals
(1.77±0.34 versus 1.69±0.35 mm,
P<0.0001, and 2.75±0.36
versus 2.65±0.38 mm, P=0.006
for MOD and MSD, respectively, in younger versus older noncarriers). In
contrast, in carriers of the R219K variant, these measurements do not
significantly change with age (1.83±0.36 versus 1.78±0.34 mm,
P=0.30, and 2.79±0.37 versus
2.75±0.37 mm, P=0.18, for MOD
and MSD, respectively, in younger versus older carriers). Thus,
vascular disease progresses more slowly with age in carriers of R219K
compared with noncarriers (Figure I; can be found Online at
www.circulationaha.org).
Replication Cohorts Show the R219K Variant
Is Associated With Decreased TG and Increased HDL-C
To confirm and replicate the relationship observed
between the R219K variant and plasma lipid levels, we genotyped this
variant in 3 small cohorts of European subjects. For every KK
individual identified, an RR individual matched for age, sex, and BMI
was selected from the same cohort.
In each of the cohorts, HDL-C was increased 10% to 15% in
KK compared with RR individuals, regardless of the presence or absence
of CAD in the cohort
(Table 5). Furthermore, TG were reduced in KK individuals in
each of the cohorts compared with the matched RR pairs. Because trends
were evident in each of the cohorts, we combined the results in a
meta-analysis to increase statistical power. HDL-C was significantly
increased in homozygous carriers compared with noncarriers
(P=0.02). Furthermore, there
was a strong trend toward decreased TG in KK individuals compared with
RR individuals.
|
Other ABCA1 cSNPs Influence Plasma
Lipid Levels and Risk of CAD
Carriers of the V825I cSNP (n=103 VI + 4 II) had no
obvious differences in lipid levels or baseline MSD or MOD
(Table 6), but they did have a significantly increased
number of events during the trial (44% versus 33% in noncarriers,
P=0.0008; odds ratio, 2.31;
95% CI, 1.41 to 3.83).
|
Although there were no differences in mean lipid levels
between the genotypes in carriers of the I883M cSNP (IM+MM,
Table 6), MM individuals (n=14) had an increased
progression in MOD (mean change, 0.53±0.79 versus 0.11±0.25 mm in
noncarriers, P<0.001) and a
cardiac event rate double that of the II individuals (n=320; 21.4%
versus 10.6%, P=0.19). The
genotype frequencies of this variant in the REGRESS population were not
consistent with Hardy-Weinberg equilibrium
(P<0.01), with too few
heterozygotes observed. These findings contrast with those of a recent
report that suggests that homozygous carriers of this cSNP have
increased
HDL-C.14
Carriers of R1587K (RK+KK) had decreased HDL-C compared with
noncarriers in an allele dose-dependent trend (0.86±0.16, 0.91±0.23,
and 0.94±0.23 mmol/L, respectively, for 58 KKs, 288 RKs, and 433 RRs;
Table 6). On multiple regression analysis including age,
BMI, smoking, and TG as covariates, the R1587K genotype remained a
significant predictor of HDL-C
(P=0.03). However, no
significant differences in CAD or events during the trial were evident
in carriers compared with noncarriers.
No homozygous carriers were detected for any of the rare
cSNPs (<10%). Heterozygous carriers of V399A had a trend toward
higher HDL-C compared with noncarriers. Interestingly, no coronary
events were observed in the VA group (versus 14% in VVs). Carriers of
V399A had half the frequency of a positive family history of CAD
(22.2% versus 49.4%, P=0.18)
and trends toward an increased baseline MOD
(Table 6) and less progression in MSD (-0.05±0.10 versus
0.08±0.19 mm in noncarriers,
P=0.16) during the trial.
However, because the number of carriers was small, conclusions
regarding the relationship of this variant to increased HDL-C and
decreased CAD cannot be drawn.
Carriers of the V771M (n=37 VM) had decreased focal
atherosclerosis (MOD) compared with noncarriers
(Table 6) and a trend toward less diffuse atherosclerosis
(increased MSD). Carriers of V771M had no difference in lipid levels
compared with noncarriers. However, all but 2 carriers of V771M were
also carriers of R219K.
Carriers of the other 3 rare variants (T774P, K776N, and
E1172D) showed no significant differences in lipid levels or CAD
compared with their respective noncarriers
(Table 6).
No carriers of S1731C were detected in the REGRESS population. This variant was initially found in 1 of our French Canadian FHA families (FHA28 ). The presence of this variant in individuals heterozygous for the R2144X ABCA1 mutation was associated with further significantly decreased HDL-C compared with R2144X carriers without this polymorphism (0.16±0.04 mmol/L, n=2, versus 0.64±0.14 mmol/L, n=10; P=0.0009). In unaffected family members, although carriers of S1731C (n=6) had slightly lower HDL-C compared with noncarriers (n=14, 1.03±0.22 versus 1.09±0.23 mmol/L), the difference was not statistically significant. This variant has been identified in other French Canadians.
The Phenotypic Effects of R219K Are Independent
of Other cSNPs
There is linkage disequilibrium between cSNPs in the
ABCA1 gene. Two rare cSNPs
(V771M and K776N) are most commonly found in individuals carrying the
R219K K allele. If all V771M and K776N carriers are excluded, the
results are unaltered, with increased MOD (1.80±0.35 versus 1.73±0.35
mm, P=0.006) and MSD
(2.76±0.36 versus 2.70±0.37 mm,
P=0.02) and lower mean TG
levels (1.71±0.75 versus 1.84±0.77 mmol/L,
P=0.02) in carriers of R219K
(n=329) compared with noncarriers (n=422).
The I883M and R1587K cSNPs are also often seen in carriers of R219K. We identified R219K carriers who do not also carry either the I883M or R1587K genotype (n=62) and compared them with the group of individuals who do not carry any of the 3 variants (n=116). MSD was still significantly increased in R219K carriers compared with noncarriers (2.81±0.37 versus 2.69±0.36 mm, P=0.04); MOD was increased in carriers (1.78±0.39 versus 1.73±0.38 mm); and TG remained significantly decreased in carriers (1.67±0.76 versus 1.97±0.74 mmol/L, P=0.02). Thus, the effects of the R219K variant described herein are not due to other cSNPs that are found in linkage disequilibrium with it.
The V825I cSNP was found to be in linkage disequilibrium with I883M. The relative risk of the V825I carriers adjusted for I883M genotype was 2.31 (95% CI, 0.78 to 6.85). Because the effects of the I883M variant were only evident in homozygous carriers, the number of individuals was too few to correct for V825I genotype.
The E1172D cSNP was found exclusively in carriers of the R1587K variant. Excluding carriers of E1172D (n=34), a trend toward decreasing HDL-C with the R1587K K allele was still evident (0.87±0.18 mmol/L in KK, 0.92±0.23 mmol/L in RK, and 0.94±0.23 mmol/L in RR, P=0.19). It is likely this no longer remained significant because the number of KK individuals (n=29) was decreased by 50%. No significant differences in lipid levels or CAD were observed for E1172D carriers compared with R1587K heterozygotes without E1172D. Thus, the effects of the R1587K cSNP are not due to the nonfunctional E1172D variant, with which it is in linkage disequilibrium.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Here we present a complete cSNP analysis of the ABCA1 gene, providing evidence that common genetic variations within ABCA1 are associated with altered plasma lipid levels and risk of CAD. The R219K variant, with a carrier frequency of 46% in European populations, is associated with a decreased severity of CAD, which manifests as decreased focal and diffuse atherosclerosis, with less progression and decreased coronary events. The increased risk associated with the wild-type allele may account for up to 5% of the population risk of coronary events. The phenotypic effects of the remaining cSNPs are less striking than those of R219K. Further analysis from additional large cohorts will be required to validate these findings.
Both the finding of decreased TG and of increased HDL-C in
younger carriers of the R219K K allele is consistent with the decreased
CAD observed in carriers of the
variant.15 16 TG
levels showed similar trends in our replication groups, and increased
HDL-C levels in R219K carriers were observed in our independent
populations. No obvious difference in cholesterol efflux level between
carriers (n=2) and noncarriers (n=4) was detected; this was probably
influenced by the small numbers and the 15% interassay coefficient
of variation in the efflux assay, which makes it impossible to detect
small differences in efflux. The phenotypic effects of this variant are
opposite to those in individuals heterozygous for
ABCA1
mutations,9 suggesting this
variant is associated with a gain of normal ABCA1 function and
increased RCT.
The lack of obvious differences in HDL-C in carriers of different cSNPs (R219K, V771M, and I883M), together with clear differences in CAD, suggests that stimulating the RCT pathway can increase the net flux of cholesterol toward the liver without altering steady-state plasma HDL-C levels. This increase in reverse cholesterol transport (RCT) activity may directly reduce the development of atherosclerosis without necessarily altering plasma lipid levels.
The mechanism underlying the decreased TG in carriers of the R219K variant is unknown. Cholesterol ester transfer protein activity results in the equilibration of the core components of lipoprotein particles.17 Cholesteryl esters are transferred from HDL to TG-rich lipoproteins, while TG are transferred in reverse. Increased ABCA1 activity, resulting in increased HDL-C, might trigger increased cholesteryl ester/TG exchange. Hepatic lipase efficiently hydrolyzes the TG component of HDL.18 Thus, increased transfer of TG to HDL may ultimately increase TG catabolism. Alternatively, alterations in ABCA1 activity have been suggested to alter intracellular lipid transport.19 20 Several genes involved in lipid metabolism are differentially regulated in ABCA1-deficient mice.19 Changes in intracellular cholesterol and phospholipid metabolism triggered by increased ABCA1 activity21 might lead to the diversion of fatty acids from TG synthesis to phospholipid synthesis, resulting in decreased TG secretion by the liver and reduced plasma TG levels.
The phenotype in individuals heterozygous for ABCA1 mutations is modified by age. In heterozygotes, the phenotype is more pronounced in older individuals.9 This suggests that ABCA1 activity may normally increase with age but that this is blunted in R219K heterozygotes. Age-related increases in the expression and activity of P-glycoprotein, another ATP-binding cassette transporter, have been described.22 23 In the present study, we show that the R219K polymorphism was also associated with an altered relationship between age and HDL-C. In noncarriers, there was a general increase in cholesterol efflux and HDL-C with age, which is suggestive of increased ABCA1 function. However, in carriers of the K allele, this age-dependent increase in both HDL-C and efflux was not evident, suggesting this variant is already associated with maximal efflux levels and is not responsive to regulation by age.
This high frequency of cSNPs emphasizes the importance of verifying that putative mutations observed within the gene are not, in fact, cSNPs. Of note, the V399A and I883M variants were shown to cosegregate on a mutation-bearing chromosome in one of the initial Tangier families described.6 The authors suggested that 1 of these 2 variants was likely the functional mutation. Yet, here we show that the V399A variant was associated with a trend toward increased HDL-C. Furthermore, we show that I883M is a common variant that is possibly associated with an increased risk of CAD in the homozygous state, although no differences in HDL-C were evident. Neither variant was associated with the marked decrease in HDL-C seen in individuals heterozygous for ABCA1 mutations. Thus, without proper analysis of missense changes in a large, ethnically matched cohort, cSNPs can be inappropriately confused with disease-causing mutations.
The distribution of cSNPs was not random
(Figure 1); they were found away from known functional
domains, such as the ATP-binding cassettes and regions where mutations
cluster.9 The one exception
to this pattern was the I883M variant, which was located just
N-terminal of the first ATP-binding cassette region, where several
mutations have been shown to occur (amino acids 909 to
93724 ). Because this variant
was associated with little functional effect, it might demarcate the
border of the region in which structural alterations significantly
impair ATP-binding cassette function. Similarly, the region containing
the V771M, T774P, and K776N variants is unlikely to be critical to
ABCA1 function, because a high degree of polymorphism is tolerated
without functional effects.
We showed that common ABCA1 cSNPs are associated with altered plasma lipid levels and severity of atherosclerosis. Specifically, the frequent R219K variant is associated with a decreased severity of atherosclerosis, a decreased risk of coronary events, decreased TG, and increased HDL-C, which is consistent with a gain of function in ABCA1. These effects were independent of any other cSNPs found in association with R219K and were seen both in different measures of CAD and in multiple cohorts. These findings emphasize the importance of common genetic variation in ABCA1 in the general population in determining plasma lipid levels and severity of CAD.
|
Acknowledgments |
|---|
This work was supported by the Canadian Institutes of Health Research (S.M.C., M.R.H.), the Heart and Stroke foundation of Canada (M.R.H.), the Canadian Networks of Centers of Excellence (NCE Genetics; M.R.H., T.J.H.), and Xenon Genetics, Inc. Dr Molhuizen and K. Zwarts were supported by the Netherlands Heart Foundation, and K. Zwarts was also supported by Dr Saal van Zwanenbergstichting. Dr Hayden is an established investigator of the BC Children’s Hospital and is an MRC-PMAC Senior Scientist. We would like to thank the REGRESS Investigators for their contribution. The REGRESS study was sponsored by Bristol Myers Squibb. Carole Dore and Yannick Renaud are thanked for their assistance.
|
Footnotes |
|---|
Dr Hayden serves as Chair of the Scientific Advisory Board and Dr Kastelein serves as a Medical Consultant for Xenon Genetics, Inc.
Figure I can be found Online Only at www.circulationaha.org
This article originally appeared Online on February 12, 2001 (Circulation. 2001;103:r13-r20).
Received December 28, 2000; revision received January 23, 2001; accepted January 23, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Miller GJ, Miller NE. Plasma high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet. 1975;1:16–19.[Medline] [Order article via Infotrieve]
2.
Wilson PWF, Abbott
RD, Castelli WP. High density lipoprotein cholesterol and mortality:
the Framingham Heart Study.
Arteriosclerosis. 1988;8:737–741.
3.
Goldbourt U, Yaari
S, Medalie JH. Isolated low HDL cholesterol as a risk factor for
coronary heart disease mortality: a 21 year follow-up of 8000 men.
Arterioscler Thromb Vasc Biol. 1997;17:107–113.
4.
Fredrickson DS,
Altrocchi PH, Avioli LV, et al. Tangier disease: combined clinical
staff conference at the National Institutes of Health.
Ann Intern Med. 1961;55:1016–1031.
5. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336–345.[Medline] [Order article via Infotrieve]
6. Bodzioch M, Orsó E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347–351.[Medline] [Order article via Infotrieve]
7. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352–355.[Medline] [Order article via Infotrieve]
8. Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 1999;354:1341–1346.[Medline] [Order article via Infotrieve]
9. Clee SM, Kastelein JJP, van Dam M, et al. HDL cholesterol levels and coronary artery disease in heterozygotes for ABCA1 mutations are predicted by cholesterol efflux levels and influenced by age. J Clin Invest. 2000;106:1263–1270.[Medline] [Order article via Infotrieve]
10. Summers KM. DNA polymorphisms in human population studies: a review. Ann Hum Biol. 1987;14:203–217.[Medline] [Order article via Infotrieve]
11.
Jukema JW,
Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by
pravastatin on the progression and regression of coronary artery
disease in symptomatic men with normal to moderately elevated serum
cholesterol levels: the Regression Growth Evaluation Statin Study
(REGRESS). Circulation. 1995;91:2528–2540.
12.
Holland PM,
Abramson RD, Watson R, et al. Detection of specific polymerase chain
reaction product by utilizing the 5'–>3' exonuclease activity of
Thermus aquaticus DNA polymerase. Proc
Natl Acad Sci
U S A. 1991;88:7276–7280.
13. Livak KJ, Marmaro J, Todd JA. Toward fully automated genome-wide polymorphism screening. Nat Genet. 1995;9:341–342.[Medline] [Order article via Infotrieve]
14.
Wang J, Burnett
JR, Near S, et al. Common and rare ABCA1 variants affecting plasma HDL
cholesterol. Arterioscler Thromb Vasc
Biol. 2000;20:1983–1989.
15.
Zilversmit DB.
Atherogenic nature of triglycerides, postprandial lipemia, and
triglyceride-rich remnant lipoproteins.
Clin Chem. 1995;41:153–158.
16.
Manninen V,
Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and
LDL cholesterol and HDL cholesterol concentrations on coronary heart
disease risk in the Helsinki Heart Study: implications for treatment.
Circulation. 1992;85:37–45.
17. Tall AR. Metabolic and genetic control of HDL cholesterol levels. J Intern Med. 1992;231:661–668.[Medline] [Order article via Infotrieve]
18. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017–1058.[Medline] [Order article via Infotrieve]
19.
McNeish J, Aiello
RJ, Guyot D, et al. High density lipoprotein deficiency and foam cell
accumulation in mice with targeted disruption of ATP-binding cassette
transporter-1. Proc Natl Acad Sci
U S A. 2000;97:4245–4250.
20. Orsó E, Broccardo C, Kaminski WE, et al. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and ABC1-deficient mice. Nat Genet. 2000;24:192–196.[Medline] [Order article via Infotrieve]
21. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25–R31.
22. Gupta S. P-glycoprotein expression and regulation: age related changes and potential effects on drug therapy. Drugs Aging. 1995;7:19–29.[Medline] [Order article via Infotrieve]
23. Witkowski JM, Miller RA. Increased function of p-glycoprotein in T lymphocyte subsets of aging mice. J Immunol. 1993;150:1296–1306.[Abstract]
24. Hayden MR, Clee SM, Brooks-Wilson A et al. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol. 2000;11:117–122.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. Y. Tsai, N. Li, A. R. Sharrett, S. Shea, D. R. Jacobs Jr, R. Tracy, D. Arnett, V. Arends, and W. Post Associations of Genetic Variants in ATP-Binding Cassette A1 and Cholesteryl Ester Transfer Protein and Differences in Lipoprotein Subclasses in the Multi-Ethnic Study of Atherosclerosis Clin. Chem., March 1, 2009; 55(3): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamada, N. Metoki, H. Yoshida, K. Satoh, K. Kato, T. Hibino, K. Yokoi, S. Watanabe, S. Ichihara, Y. Aoyagi, et al. Genetic Factors for Ischemic and Hemorrhagic Stroke in Japanese Individuals Stroke, August 1, 2008; 39(8): 2211 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frikke-Schmidt, B. G. Nordestgaard, G. B. Jensen, R. Steffensen, and A. Tybjaerg-Hansen Genetic Variation in ABCA1 Predicts Ischemic Heart Disease in the General Population Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 180 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kyriakou, D. E. Pontefract, E. Viturro, C. P. Hodgkinson, R. C. Laxton, N. Bogari, G. Cooper, M. Davies, J. Giblett, I. N.M. Day, et al. Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients Hum. Mol. Genet., June 15, 2007; 16(12): 1412 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soro-Paavonen, J. Naukkarinen, M. Lee-Rueckert, H. Watanabe, E. Rantala, S. Soderlund, A. Hiukka, P. T. Kovanen, M. Jauhiainen, L. Peltonen, et al. Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL J. Lipid Res., June 1, 2007; 48(6): 1409 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kiss, N. Kavaslar, K.-i. Okuhira, M. W. Freeman, S. Walter, R. W. Milne, R. McPherson, and Y. L. Marcel Genetic Etiology of Isolated Low HDL Syndrome: Incidence and Heterogeneity of Efflux Defects Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Oram and A. M. Vaughan ATP-Binding Cassette Cholesterol Transporters and Cardiovascular Disease Circ. Res., November 10, 2006; 99(10): 1031 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L.E. Klos, C. F. Sing, E. Boerwinkle, S. C. Hamon, T. J. Rea, A. Clark, M. Fornage, and J. E. Hixson Consistent Effects of Genes Involved in Reverse Cholesterol Transport on Plasma Lipid and Apolipoprotein Levels in CARDIA Participants Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Van Eck, R. R. Singaraja, D. Ye, R. B. Hildebrand, E. R. James, M. R. Hayden, and T. J.C. Van Berkel Macrophage ATP-Binding Cassette Transporter A1 Overexpression Inhibits Atherosclerotic Lesion Progression in Low-Density Lipoprotein Receptor Knockout Mice Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 929 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Koldamova, M. Staufenbiel, and I. Lefterov Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice J. Biol. Chem., December 30, 2005; 280(52): 43224 - 43235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pluskota, O. I. Stenina, I. Krukovets, D. Szpak, E. J. Topol, and E. F. Plow Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function Blood, December 1, 2005; 106(12): 3970 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frikke-Schmidt, B. G. Nordestgaard, P. Schnohr, R. Steffensen, and A. Tybjaerg-Hansen Mutation in ABCA1 Predicted Risk of Ischemic Heart Disease in the Copenhagen City Heart Study Population J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1516 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Kelleher, E. K. Silverman, T. Broekelmann, A. A. Litonjua, M. Hernandez, J. S. Sylvia, J. Stoler, J. J. Reilly, H. A. Chapman, F. E. Speizer, et al. A Functional Mutation in the Terminal Exon of Elastin in Severe, Early-Onset Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol., October 1, 2005; 33(4): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Albrecht, J. H. McVey, J. I. Elliott, A. Sardini, I. Kasza, A. D. Mumford, R. P. Naoumova, E. G. D. Tuddenham, K. Szabo, and C. F. Higgins A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome Blood, July 15, 2005; 106(2): 542 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zareparsi, M. Buraczynska, K. E.H. Branham, S. Shah, D. Eng, M. Li, H. Pawar, B. M. Yashar, S. E. Moroi, P. R. Lichter, et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration Hum. Mol. Genet., June 1, 2005; 14(11): 1449 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Woll, N. Q. Hanson, V. L. Arends, and M. Y. Tsai Effect of Two Common Polymorphisms in the ATP Binding Cassette Transporter A1 Gene on HDL-Cholesterol Concentration Clin. Chem., May 1, 2005; 51(5): 907 - 909. [Full Text] [PDF]
|
|
|
|
|
|
T. Fasano, L. Bocchi, L. Pisciotta, S. Bertolini, and S. Calandra Denaturing high-performance liquid chromatography in the detection of ABCA1 gene mutations in familial HDL deficiency J. Lipid Res., April 1, 2005; 46(4): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Koldamova, I. M. Lefterov, M. Staufenbiel, D. Wolfe, S. Huang, J. C. Glorioso, M. Walter, M. G. Roth, and J. S. Lazo The Liver X Receptor Ligand T0901317 Decreases Amyloid {beta} Production in Vitro and in a Mouse Model of Alzheimer's Disease J. Biol. Chem., February 11, 2005; 280(6): 4079 - 4088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kyriakou, C. Hodgkinson, D. E. Pontefract, S. Iyengar, W. M. Howell, Y.-k. Wong, P. Eriksson, and S. Ye Genotypic Effect of the -565C>T Polymorphism in the ABCA1 Gene Promoter on ABCA1 Expression and Severity of Atherosclerosis Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 418 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Fitzgerald, K.-i. Okuhira, G. F. Short III, J. J. Manning, S. A. Bell, and M. W. Freeman ATP-binding Cassette Transporter A1 Contains a Novel C-terminal VFVNFA Motif That Is Required for Its Cholesterol Efflux and ApoA-I Binding Activities J. Biol. Chem., November 12, 2004; 279(46): 48477 - 48485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J McCarthy, A Parker, R Salem, D J Moliterno, Q Wang, E F Plow, S Rao, G Shen, W J Rogers, L K Newby, et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes J. Med. Genet., May 1, 2004; 41(5): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-A. Tregouet, S. Ricard, V. Nicaud, I. Arnould, S. Soubigou, M. Rosier, N. Duverger, O. Poirier, S. Mace, F. Kee, et al. In-Depth Haplotype Analysis of ABCA1 Gene Polymorphisms in Relation to Plasma ApoA1 Levels and Myocardial Infarction Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Ghiu, R. E. Ferrell, O. Kulaputana, D. A. Phares, and J. M. Hagberg Selected genetic polymorphisms and plasma coagulation factor VII changes with exercise training J Appl Physiol, March 1, 2004; 96(3): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hattori, T. Kujiraoka, T. Egashira, E. Saito, T. Fujioka, S. Takahashi, M. Ito, J. A. Cooper, I. P. Stepanova, M. N. Nanjee, et al. Association of Coronary Heart Disease with Pre-{beta}-HDL Concentrations in Japanese Men Clin. Chem., March 1, 2004; 50(3): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ho Hong, J. Rhyne, and M. Miller Novel Polypyrimidine Variation (IVS46: del T -39...-46) in ABCA1 Causes Exon Skipping and Contributes to HDL Cholesterol Deficiency in a Family With Premature Coronary Disease Circ. Res., November 14, 2003; 93(10): 1006 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Morabia, E. Cayanis, M. C. Costanza, B. M. Ross, M. S. Flaherty, G. B. Alvin, K. Das, and T. C. Gilliam Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors Hum. Mol. Genet., November 1, 2003; 12(21): 2733 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Singaraja, L. R. Brunham, H. Visscher, J. J.P. Kastelein, and M. R. Hayden Efflux and Atherosclerosis: The Clinical and Biochemical Impact of Variations in the ABCA1 Gene Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1322 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Joyce, L. Freeman, H. B. Brewer Jr, and S. Santamarina-Fojo Study of ABCA1 Function in Transgenic Mice Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Koldamova, I. M. Lefterov, M. D. Ikonomovic, J. Skoko, P. I. Lefterov, B. A. Isanski, S. T. DeKosky, and J. S. Lazo 22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid beta Secretion J. Biol. Chem., April 4, 2003; 278(15): 13244 - 13256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Mulligan, M. T. Flowers, A. Tebon, J. J. Bitgood, C. Wellington, M. R. Hayden, and A. D. Attie ABCA1 Is Essential for Efficient Basolateral Cholesterol Efflux during the Absorption of Dietary Cholesterol in Chickens J. Biol. Chem., April 4, 2003; 278(15): 13356 - 13366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Woll, N. Q. Hanson, and M. Y. Tsai Absence of ABCA1 Mutations in Individuals with Low Serum HDL-Cholesterol Clin. Chem., March 1, 2003; 49(3): 521 - 522. [Full Text] [PDF]
|
|
|
|
|
|
A Cenarro, M Artieda, S Castillo, P Mozas, G Reyes, D Tejedor, R Alonso, P Mata, M Pocovi, and F Civeira A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia J. Med. Genet., March 1, 2003; 40(3): 163 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rigot, Y. Hamon, O. Chambenoit, M. Alibert, N. Duverger, and G. Chimini Distinct sites on ABCA1 control distinct steps required for cellular release of phospholipids J. Lipid Res., December 1, 2002; 43(12): 2077 - 2086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. See, R. A. Caday-Malcolm, R. R. Singaraja, S. Zhou, A. Silverston, M. T. Huber, J. Moran, E. R. James, R. Janoo, J. M. Savill, et al. Protein Kinase A Site-specific Phosphorylation Regulates ATP-binding Cassette A1 (ABCA1)-mediated Phospholipid Efflux J. Biol. Chem., October 25, 2002; 277(44): 41835 - 41842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Attie, J. P. Kastelein, and M. R. Hayden Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis J. Lipid Res., November 1, 2001; 42(11): 1717 - 1726. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||